Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)
Clinical trial NCT02362594 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02362594
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-07-16
- Primary completion
- 2018-01-08
- Enrollment
- 1019
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.